How have ONVO shares performed in 2024?

Organovo's stock was trading at $1.11 at the start of the year. Since then, ONVO shares have increased by 0.9% and is now trading at $1.12. View the best growth stocks for 2024 here .

When is Organovo's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 11th 2024. View our ONVO earnings forecast .

How were Organovo's earnings last quarter?

Organovo Holdings, Inc. (NASDAQ:ONVO) posted its earnings results on Thursday, February, 8th. The medical research company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.01. The medical research company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.08 million.

When did Organovo's stock split?

Organovo's stock reverse split on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Taylor Crouch's approval rating as Organovo's CEO?

3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com . Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Organovo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI) , NVIDIA (NVDA) , Aerojet Rocketdyne (AJRD) , Blackstone (BX) , LADENBURG THALM/SH SH (LTS) , Advanced Micro Devices (AMD) , Exelixis (EXEL) , Micron Technology (MU) , Novavax (NVAX) and OPKO Health (OPK) .

How do I buy shares of Organovo?

Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ONVO

Organovo (ONVO) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ONVO Stock Alerts

$1.12

-0.03 (-2.61%)

(As of 04/17/2024 ET)

Compare

Today's Range: $1.05
▼
$1.21
50-Day Range: $0.90
▼
$1.35
52-Week Range: $0.89
▼
$2.23

Volume: 544,306 shs
Average Volume: 867,298 shs
Market Capitalization: $11.24 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Organovo alerts:

Organovo MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.61% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.41
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.74) to ($1.41) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.47 out of 5 stars

Medical Sector

869th out of 914 stocks

Biological Products, Except Diagnostic Industry

135th out of 138 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Organovo.

3.0

Short Interest

Percentage of Shares Shorted
1.61% of the outstanding shares of Organovo have been sold short.
Short Interest Ratio / Days to Cover
Organovo has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Organovo has recently increased by 19.57%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Organovo does not currently pay a dividend.
Dividend Growth
Organovo does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ONVO.

3.0

News and Social Media Coverage

News Sentiment
Organovo has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Organovo this week, compared to 0 articles on an average week.
Search Interest
3 people have searched for ONVO on MarketBeat in the last 30 days.
MarketBeat Follows
15 people have added Organovo to their MarketBeat watchlist in the last 30 days. This is an increase of 1,400% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Organovo insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.00% of the stock of Organovo is held by insiders.
Percentage Held by Institutions
Only 8.23% of the stock of Organovo is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Organovo are expected to grow in the coming year, from ($1.74) to ($1.41) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Organovo is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Organovo is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Organovo has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Organovo Stock (NASDAQ:ONVO)

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

ONVO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ONVO Stock News Headlines

April 15, 2024 | msn.com

Why Organovo Stock Is Up Today

April 15, 2024 | reuters.com

Organovo's fatty liver disease drug meets main goal in mid-stage study

April 17, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 15, 2024 | globenewswire.com

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

April 10, 2024 | americanbankingnews.com

StockNews.com Initiates Coverage on Organovo (NASDAQ:ONVO)

February 24, 2024 | benzinga.com

Organovo Holdings Stock (NASDAQ:ONVO) Earnings Dates and Earning Calls

February 10, 2024 | finance.yahoo.com

Organovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

February 9, 2024 | morningstar.com

Organovo Holdings Inc ONVO

April 17, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 9, 2024 | finance.yahoo.com

ONVO Continues Progress

February 8, 2024 | sfgate.com

Organovo: Fiscal Q3 Earnings Snapshot

February 8, 2024 | msn.com

Organovo Holdings Unveils Corporate Presentation Online

January 25, 2024 | finance.yahoo.com

Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress

January 9, 2024 | finance.yahoo.com

Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress

December 7, 2023 | finanznachrichten.de

Organovo, Inc.: Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

December 6, 2023 | finance.yahoo.com

Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results

November 13, 2023 | msn.com

OVNO Continues Developing Breakthrough Treatments

November 13, 2023 | finance.yahoo.com

CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan

November 11, 2023 | finance.yahoo.com

Organovo Holdings Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.38 loss in 2Q 2023)

November 8, 2023 | finance.yahoo.com

Organovo Highlights FXR314 Combination Therapy Potential and Plan

November 7, 2023 | msn.com

ONVO, FATH and BYU among mid-day movers

October 10, 2023 | finance.yahoo.com

ONVO: A Company With Great Technology to Impact Health Care

September 8, 2023 | finance.yahoo.com

Organovo to Participate in the H.C. Wainwright Global Investment Conference

August 25, 2023 | finance.yahoo.com

Is Organovo Holdings (ONVO) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap

August 23, 2023 | finance.yahoo.com

Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

August 16, 2023 | msn.com

Onvo receives $3 million grant from PennDOT to enhance electric vehicle charging infrastructure

July 29, 2023 | seekingalpha.com

ONVO Organovo Holdings, Inc.

See More Headlines

Receive ONVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/08/2024
Today: 4/17/2024
Next Earnings (Estimated): 7/11/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:ONVO
CUSIP: N/A
CIK: 1497253
Web: www.organovo.com
Phone: (858) 224-1000
Fax: N/A
Employees: 18
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,260,000.00
Net Margins: N/A
Pretax Margin: -7,885.54%
Return on Equity: -182.88%
Return on Assets: -138.52%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.67
Quick Ratio: 3.67

Sales & Book Value

Annual Sales: $370,000.00
Price / Sales: 32.56
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.76 per share
Price / Book: 0.68

Miscellaneous

Outstanding Shares: 10,040,000
Free Float: 9,538,000
Market Cap: $12.05 million
Optionable: Optionable
Beta: 0.91

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Keith E. Murphy (Age 52)
Company Secretary & Executive Chairman
Comp: $626.24k
Ms. Vaidehi Joshi (Age 38)
Director of Discovery Biology & Director
Comp: $91.4k
Mr. Thomas P. Hess CPA (Age 60)
MBA, President & CFO
Dr. Curtis M. Tyree Ph.D.
Senior Vice President of Strategy & Business Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ONVO Stock Analysis - Frequently Asked Questions

How have ONVO shares performed in 2024?: Organovo's stock was trading at $1.11 at the start of the year. Since then, ONVO shares have increased by 0.9% and is now trading at $1.12.
View the best growth stocks for 2024 here.
When is Organovo's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, July 11th 2024.
View our ONVO earnings forecast.
How were Organovo's earnings last quarter?: Organovo Holdings, Inc. (NASDAQ:ONVO) posted its earnings results on Thursday, February, 8th. The medical research company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.01. The medical research company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.08 million.
When did Organovo's stock split?: Organovo's stock reverse split on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Taylor Crouch's approval rating as Organovo's CEO?: 3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Organovo own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK).
How do I buy shares of Organovo?: Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ONVO) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Organovo (ONVO) Stock Price, News & Analysis

Organovo MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Organovo Stock (NASDAQ:ONVO)

ONVO Stock Price History

ONVO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ONVO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™